| Literature DB >> 26273587 |
Paolo Cremaschi1, Roberta Carriero1, Stefania Astrologo1, Caterina Colì1, Antonella Lisa1, Silvia Parolo1, Silvia Bione1.
Abstract
In the past few years, the role of long noncoding RNAs (lncRNAs) in tumor development and progression has been disclosed although their mechanisms of action remain to be elucidated. An important contribution to the comprehension of lncRNAs biology in cancer could be obtained through the integrated analysis of multiple expression datasets. However, the growing availability of public datasets requires new data mining techniques to integrate and describe relationship among data. In this perspective, we explored the powerness of the Association Rule Mining (ARM) approach in gene expression data analysis. By the ARM method, we performed a meta-analysis of cancer-related microarray data which allowed us to identify and characterize a set of ten lncRNAs simultaneously altered in different brain tumor datasets. The expression profiles of the ten lncRNAs appeared to be sufficient to distinguish between cancer and normal tissues. A further characterization of this lncRNAs signature through a comodulation expression analysis suggested that biological processes specific of the nervous system could be compromised.Entities:
Mesh:
Substances:
Year: 2015 PMID: 26273587 PMCID: PMC4530207 DOI: 10.1155/2015/146250
Source DB: PubMed Journal: Biomed Res Int Impact factor: 3.411
Figure 1Distribution of the identified 102 nonredundant rules. (a) Distribution of identified rules based on the number of lncRNAs contained; (b) distribution of the identified rules based on support thresholds.
Figure 2Distribution of the results of the 100 simulation runs. (a) Distribution of the number of redundant rules produced in the simulation runs; (b) distribution of the number of lncRNAs contained in the wider rule in each simulation run.
List of the 13 lncRNAs.
| Number | lncRNA symbol | lncRNA name | Reference |
|---|---|---|---|
| 1 | CRNDE | Colorectal neoplasia differentially expressed | Ellis et al., 2012 [ |
| 2 | DLEU2 | Deleted in lymphocytic leukemia 2 | Lerner et al., 2009 [ |
| 3 | KRTAP5-AS1 | KRTAP5-1/KRTAP5-2 antisense RNA 1 | |
| 4 | LINC00301 | Long intergenic non-protein coding RNA 301 | |
| 5 | MEG3 | Maternally expressed 3 | Wang et al., 2012 [ |
| 6 | OIP5-AS1 | OIP5 antisense RNA 1 | |
| 7 | PART1 | Prostate androgen-regulated transcript 1 | Zhang et al., 2013 [ |
| 8 | PPP1R26-AS1 | PPP1R26 antisense RNA 1 | |
| 9 | RFPL1S | RFPL1 antisense RNA 1 | Zhang et al., 2012 [ |
| 10 | RUSC1-AS1 | RUSC1 antisense RNA 1 | |
| 11 | SYN2∗ | Synapsin II | |
| 12 | UBL7-AS1 | UBL7 antisense RNA 1 | |
| 13 | UHRF1∗ | Ubiquitin-like with PHD and ring finger domains 1 |
∗lncRNA not distinguishable from the protein coding isoform.
LFC of the 13 lncRNAs in GEO datasets.
| lncRNA symbol | Gene ID | lncRNA name | GDS1962 | GDS3592 | ||||
|---|---|---|---|---|---|---|---|---|
| Astrocytoma (grade II) | Astrocytoma (grade III) | Glioblastoma (grade IV) | Oligodendroglioma (grade II) | Oligodendroglioma (grade III) | Ovarian cancer epithelial cells | |||
| OIP5-AS1 | 729082 | OIP5 antisense RNA 1 | −1 | −1.3 | −1.5 | −1 | −1.5 | −1.3 |
| RFPL1S | 10740 | RFPL1 antisense RNA 1 | −2.5 | −2.6 | −3.8 | −2.3 | −3.3 | −2.5 |
| MEG3 | 55384 | Maternally expressed 3 | −2.4 | −2.8 | −2.7 | −2.6 | −2.7 | 1.2 |
| KRTAP5-AS1 | 338651 | KRTAP5-1/KRTAP5-2 antisense RNA 1 | −1.7 | −1.7 | −2 | −1.1 | −1.8 | 1 |
| LINC00301 | 283197 | Long intergenic non-protein coding RNA 301 | −2.2 | −1.5 | −1.9 | −1.4 | −2.1 | 1.9 |
| PART1 | 25859 | Prostate androgen-regulated transcript 1 | −1.4 | −1.7 | −2 | −1.4 | −1.9 | 2.4 |
| PPP1R26-AS1 | 100506599 | PPP1R26 antisense RNA 1 | −1.4 | −1.4 | −1.2 | −1.1 | −1.4 | 1.9 |
| SYN2 | 6854 | Synapsin II | −2.6 | −2.6 | −4 | −2.5 | −3.8 | 2.2 |
| CRNDE | 643911 | Colorectal neoplasia differentially expressed | 3.2 | 3.6 | 4.2 | 1.8 | 3.7 | −4.3 |
| RUSC1-AS1 | 284618 | RUSC1 antisense RNA 1 | 1.6 | 1.5 | 1.2 | 1.4 | 1.5 | 2 |
| UBL7-AS1 | 440288 | UBL7 antisense RNA 1 | 1.8 | 1.6 | 1.5 | 1.4 | 1.8 | 1.6 |
| DLEU2 | 8847 | Deleted in lymphocytic leukemia 2 | 1 | 1 | 1.5 | 1 | 1.4 | 1.5 |
| UHRF1 | 29128 | Ubiquitin-like with PHD and ring finger domains 1 | 2.5 | 3.6 | 4 | 3.1 | 3.8 | 3.4 |
LFC of the 13 lncRNAs in different brain cancer datasets.
| OIP5-AS1 | RFPL1S | MEG3 | KRTAP5-AS1 | LINC00301 | PART1 | PPP1R26-AS1 | SYN2 | CRNDE | RUSC1-AS1 | UBL7-AS1 | DLEU2 | UHRF1 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| GDS1962 | Astrocytoma (grade II) | −1.0 | −2.5 | −2.4 | −1.7 | −2.2 | −1.4 | −1.4 | −2.6 | 3.2 | 1.6 | 1.8 | 1.0 | 2.5 |
| Astrocytoma (grade III) | −1.3 | −2.6 | −2.8 | −1.7 | −1.5 | −1.7 | −1.4 | −2.6 | 3.6 | 1.5 | 1.6 | 1.0 | 3.6 | |
| Glioblastoma (grade IV) | −1.5 | −3.8 | −2.7 | −2.0 | −1.9 | −2.0 | −1.2 | −4.0 | 4.2 | 1.2 | 1.5 | 1.5 | 4.0 | |
| Oligodendroglioma (grade II) | −1.0 | −2.3 | −2.6 | −1.1 | −1.4 | −1.4 | −1.1 | −2.5 | 1.8 | 1.4 | 1.4 | 1.0 | 3.1 | |
| Oligodendroglioma (grade III) | −1.5 | −3.3 | −2.7 | −1.8 | −2.1 | −1.9 | −1.4 | −3.8 | 3.7 | 1.5 | 1.8 | 1.4 | 3.8 | |
|
| ||||||||||||||
| E-GEOD-16011 | Astrocytoma (grade II) | −1.0 | −3.8 | −2.7 | −1.0 | −0.3 | −2.9 | −0.3 | −3.8 | 2.8 | n.s. | 0.5 | 1.4 | 2.9 |
| Astrocytoma (grade III) | −1.5 | −4.6 | −3.8 | −1.1 | −0.3 | −3.4 | −0.4 | −5.4 | 3.7 | 0.8 | 0.9 | 1.9 | 3.2 | |
| Glioblastoma (grade IV) | −1.8 | −4.8 | −3.7 | −1.1 | −0.3 | −3.3 | −0.2 | −5.4 | 4.4 | n.s. | 0.8 | 1.4 | 3.6 | |
| Oligodendroglioma (grade II) | −1.0 | −3.1 | −2.7 | −1.0 | −0.3 | −3.1 | −0.3 | −3.9 | n.s. | 1.0 | 0.7 | 1.6 | 3.7 | |
| Oligodendroglioma (grade III) | −1.5 | −3.6 | −3.7 | −1.0 | −0.3 | −3.3 | −0.3 | −5.1 | 2.8 | 1.1 | 0.8 | 1.8 | 3.4 | |
|
| ||||||||||||||
| RNAseq | Astrocytoma | −0.3 | −2.2 | n.s. | −3.0 | n.s. | −3.0 | n.s. | −2.5 | 4.7 | 1.5 | 2.0 | 2.3 | 2.5 |
| Glioblastoma | −0.3 | −4.7 | 0.6 | −3.2 | n.s. | −4.2 | n.s. | −2.2 | 4.7 | n.s. | 1.8 | 2.1 | 1.8 | |
| Oligodendroglioma | −0.4 | −1.7 | −2.0 | −1.4 | n.s. | −1.0 | n.s. | −3.8 | 4.9 | 1.0 | 2.3 | 4.0 | 2.5 | |
Figure 3Genomic alignments of RNA-seq reads corresponding to the lncRNAs: (a) CRNDE and (b) PART1 in the three brain tumors types. The visualization of the alignment was obtained with the IGV software.
Figure 4Principal Component Analysis (PCA) performed on the GEO dataset GDS1962 (a and b) and ArrayExpress dataset E-GEOD-16011 (c and d) considering intensity values of all probes (a and c) or only probes corresponding to the 10 lncRNAs (b and d). Red dots correspond to brain tumor samples and black dots correspond to normal brain samples.
Figure 5Enrichment analysis of downregulated genes from comodulation results.
Figure 6Gene networks of the selected 18 genes obtained by the tools: (a) STRING 9.1 and (b) GeneMANIA.